FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2061325013> ?p ?o ?g. }

• W2061325013 endingPage "496" @default.
• W2061325013 startingPage "490" @default.
• W2061325013 abstract "Interleukin-32 (IL-32) is a proinflammatory cytokine that acts as a significant pathogenetic factor in various diseases and malignancies. However, the clinical effect of IL‑32 expression in renal cell carcinoma (RCC) has not previously been investigated. The aim of the present study was to examine the significance of IL-32 overexpression in localized clear cell RCC (CCRCC). We examined 112 patients with localized CCRCC who underwent nephrectomy. The clinicopathological data were obtained by retrospective review and the expression levels of IL-32 were studied by immunohistochemistry. Tumors were classified according to staining intensity (0, no staining intensity; 1, weak; 2, intermediate; 3, strong). The cases with staining intensities from 0 to 2 comprised the IL-32 low-expression group (LEG), whereas those with a staining intensity of 3 comprised the IL-32 high-expression group (HEG). Correlations between IL-32 expression and clinicopathological parameters were determined. Staining intensities were determined for all cases as follows: 26 cases (23.2%) (score 0), 43 cases (38.4%) (score 1), 31 cases (27.7%) (score 2) and 12 cases (10.7%) (score 3). IL-32 HEG exhibited a higher recurrence rate compared to the IL-32 LEG (50 vs. 13%, P=0.001). For survival rates, the 5-year recurrence-free survival (RFS), disease-specific survival (DSS) and overall survival (OS) rates were lower in the IL-32 HEG group compared with the IL-32 LEG group (RFS, P=0.001; DSS, P<0.001; OS, P=0.026, respectively). Univariate analyses revealed that Fuhrman nuclear grade and a high IL-32 expression were significant prognostic factors for predicting RFS, DSS and OS in CCRCC, whereas multivariate analyses indicated that Fuhrman nuclear grade and high IL-32 expression were still independent risk factors. In conclusion, IL-32 overexpression was associated with high recurrence rates and low RFS, DSS and OS, indicating that it may be a novel prognostic factor for predicting outcomes in patients with CCRCC." @default.
• W2061325013 created "2016-06-24" @default.
• W2061325013 creator A5007640483 @default.
• W2061325013 creator A5039448459 @default.
• W2061325013 creator A5066903821 @default.
• W2061325013 creator A5069919736 @default.
• W2061325013 creator A5075048652 @default.
• W2061325013 creator A5079460563 @default.
• W2061325013 creator A5084818663 @default.
• W2061325013 date "2011-12-02" @default.
• W2061325013 modified "2023-10-16" @default.
• W2061325013 title "Overexpression of IL-32 is a novel prognostic factor in patients with localized clear cell renal cell carcinoma" @default.
• W2061325013 cites W1493964345 @default.
• W2061325013 cites W1542584728 @default.
• W2061325013 cites W1548588240 @default.
• W2061325013 cites W1581463157 @default.
• W2061325013 cites W1902994240 @default.
• W2061325013 cites W1972996521 @default.
• W2061325013 cites W1973394808 @default.
• W2061325013 cites W1975350793 @default.
• W2061325013 cites W1982117553 @default.
• W2061325013 cites W2021132826 @default.
• W2061325013 cites W2030832631 @default.
• W2061325013 cites W2039545078 @default.
• W2061325013 cites W2039773242 @default.
• W2061325013 cites W2057567734 @default.
• W2061325013 cites W2060639513 @default.
• W2061325013 cites W2082061020 @default.
• W2061325013 cites W2083874662 @default.
• W2061325013 cites W2083887116 @default.
• W2061325013 cites W2097512250 @default.
• W2061325013 cites W2099088585 @default.
• W2061325013 cites W2102900043 @default.
• W2061325013 cites W2110380269 @default.
• W2061325013 cites W2115677056 @default.
• W2061325013 cites W2119770043 @default.
• W2061325013 cites W2139115185 @default.
• W2061325013 cites W2143494794 @default.
• W2061325013 cites W2149883686 @default.
• W2061325013 cites W2155509911 @default.
• W2061325013 cites W2155736175 @default.
• W2061325013 cites W2157037524 @default.
• W2061325013 cites W2158734599 @default.
• W2061325013 cites W2166483338 @default.
• W2061325013 cites W2170264130 @default.
• W2061325013 doi "https://doi.org/10.3892/ol.2011.511" @default.
• W2061325013 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3362389" @default.
• W2061325013 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22740938" @default.
• W2061325013 hasPublicationYear "2011" @default.
• W2061325013 type Work @default.
• W2061325013 sameAs 2061325013 @default.
• W2061325013 citedByCount "21" @default.
• W2061325013 countsByYear W20613250132013 @default.
• W2061325013 countsByYear W20613250132015 @default.
• W2061325013 countsByYear W20613250132016 @default.
• W2061325013 countsByYear W20613250132017 @default.
• W2061325013 countsByYear W20613250132018 @default.
• W2061325013 countsByYear W20613250132020 @default.
• W2061325013 countsByYear W20613250132022 @default.
• W2061325013 countsByYear W20613250132023 @default.
• W2061325013 crossrefType "journal-article" @default.
• W2061325013 hasAuthorship W2061325013A5007640483 @default.
• W2061325013 hasAuthorship W2061325013A5039448459 @default.
• W2061325013 hasAuthorship W2061325013A5066903821 @default.
• W2061325013 hasAuthorship W2061325013A5069919736 @default.
• W2061325013 hasAuthorship W2061325013A5075048652 @default.
• W2061325013 hasAuthorship W2061325013A5079460563 @default.
• W2061325013 hasAuthorship W2061325013A5084818663 @default.
• W2061325013 hasBestOaLocation W20613250131 @default.
• W2061325013 hasConcept C121608353 @default.
• W2061325013 hasConcept C126322002 @default.
• W2061325013 hasConcept C142724271 @default.
• W2061325013 hasConcept C144301174 @default.
• W2061325013 hasConcept C204232928 @default.
• W2061325013 hasConcept C2777472916 @default.
• W2061325013 hasConcept C2777546739 @default.
• W2061325013 hasConcept C2778560582 @default.
• W2061325013 hasConcept C2780091579 @default.
• W2061325013 hasConcept C2780227381 @default.
• W2061325013 hasConcept C2781018059 @default.
• W2061325013 hasConcept C2781278892 @default.
• W2061325013 hasConcept C29537977 @default.
• W2061325013 hasConcept C38180746 @default.
• W2061325013 hasConcept C67082663 @default.
• W2061325013 hasConcept C71924100 @default.
• W2061325013 hasConcept C74864618 @default.
• W2061325013 hasConcept C90924648 @default.
• W2061325013 hasConceptScore W2061325013C121608353 @default.
• W2061325013 hasConceptScore W2061325013C126322002 @default.
• W2061325013 hasConceptScore W2061325013C142724271 @default.
• W2061325013 hasConceptScore W2061325013C144301174 @default.
• W2061325013 hasConceptScore W2061325013C204232928 @default.
• W2061325013 hasConceptScore W2061325013C2777472916 @default.
• W2061325013 hasConceptScore W2061325013C2777546739 @default.
• W2061325013 hasConceptScore W2061325013C2778560582 @default.
• W2061325013 hasConceptScore W2061325013C2780091579 @default.
• W2061325013 hasConceptScore W2061325013C2780227381 @default.
• W2061325013 hasConceptScore W2061325013C2781018059 @default.

• next